Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial (2023)
Attributed to:
Paediatric and adolescent infections
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciad346
PubMed Identifier: 37280040
Publication URI: http://europepmc.org/abstract/MED/37280040
Type: Journal Article/Review
Parent Publication: Clinical Infectious Diseases
Issue: 9